Apelin plasma levels predict arrhythmia recurrence in patients with persistent atrial fibrillation

International Journal of Immunopathology and Pharmacology

Volumn 23, Issue 3, 2010, Pages 917-925

  Falcone, Colomba ^a,b,c   Buzzi, M P ^a   D'Angelo, A ^a   Schirinzi, S ^a   Falcone, R ^a   Rordorf, R ^b   Capettini, A C ^a   Landolina, M ^b   Storti, C ^a   Pelissero, G ^c  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

Apelin; Atrial fibrillation; Brain natriuretic peptide; Prognosis

Indexed keywords

APELIN; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; HIGH SENSITIVITY C REACTIVE PROTEIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLOOD LEVEL; CARDIOVERSION; DISEASE DURATION; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RISK FACTOR;

EID: 78149253076     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201002300328     Document Type: Article

References (29)

1. Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for human APJ receptor. Biochem Biophys Res Commun 1998; 251:471-6.
2. Masri B, Knibiehler B, Audigier Y. Apelin signalling: a promising pathway from cloning to pharmacology. Cell Signal 2005; 17:415-26.
3. Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther 2005; 107:198-211.
4. Carpéné C, Dray C, Attané C, Valet P, Portillo MP, Churruca I, Milagro FI, Castan-Laurell I. Expanding role for the apelin/APJ system in physiopathology. J Physiol Biochem 2007; 63:359-73.
5. Chandrasekaran B, Dar O, McDonagh T. The role of apelin in cardiovascular function and heart failure. Eur J Heart Fail 2008; 10:725-32.
6. Szokodi I, Tavi P, Földes G, et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 2002; 91:434-40.
7. Dai T, Ramirez-Correa G, Gao WD. Apelin increases contractility in failing cardiac muscle. Eur J Pharmacol 2006; 553:222-8.
8. Farkasfalvi K, Stagg MA, Coppen SR, et al. Direct effects of apelin on cardiomyocyte contractility and electrophysiology. Biochem Biophys Res Commun 2007; 357:889-95.
9. Chun HJ, Ali ZA, Kojima Y, et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest 2008; 118:3343-54.
10. Japp AG, Newby DE. The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential. Biochem Pharmacol 2008; 75:1882-92.
11. Földes G, Horkay F, Szokodi I, et al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun 2003; 308:480-5.
12. Ellinor PT, Low AF, Macrae CA. Reduced apelin levels in lone atrial fibrillation. Eur Heart J 2006; 27:222-6.
13. Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail 2006; 8:355-60.
14. Francia P, Salvati A, Balla C, et al. Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin. Eur J Heart Fail 2007; 9:306-9.
15. Chen MM, Ashley EA, Deng DX, et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 2003; 108:1432-9.
16. Charles CJ. Putative role for apelin in pressure/volume homeostasis and cardiovascular disease. Cardiovasc Hematol Agents Med Chem 2007; 5:1-10.
17. Mabuchi N, Tsutamoto T, Maeda K, Kinoshita M. Plasma cardiac natriuretic peptides as biochemical markers of recurrence of atrial fibrillation in patients with mild congestive heart failure. Jpn Circ J 2000; 64:765-71.
18. Beck-da-Silva L, de Bold A, Fraser M, Williams K, Haddad H. Brain natriuretic peptide predicts successful cardioversion in patients with atrial fibrillation and maintenance of sinus rhythm. Can J Cardiol 2004; 20:1245-8.
19. Lellouche N, Berthier R, Mekontso-Dessap A, Braconnier F, Monin JL, Duval AM, Dubois-Randé JL, Guéret P, Garot J. Usefulness of plasma B-type natriuretic peptide in predicting recurrence of atrial fibrillation one year after external cardioversion. Am J Cardiol 2005; 95:1380-2.
20. Malouf JF, Kanagala R, Al Atawi FO, et al. High sensitivity C-reactive protein: a novel predictor for recurrence of atrial fibrillation after successful cardioversion. J Am Coll Cardiol 2005; 46:1284-7.
21. Wazni O, Martin DO, Marrouche NF, Shaaraoui M, Chung MK, Almahameed S, Schweikert RA, Saliba WI, Natale A. C reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion. Heart 2005; 91:1303-5.
22. Liu T, Li G, Li L, Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol 2007; 49:1642-8.
23. Korantzopoulos P, Kalantzi K, Siogas K, Goudevenos JA. Long-term prognostic value of baseline C-reactive protein in predicting recurrence of atrial fibrillation after electrical cardioversion. Pacing Clin Electrophysiol 2008; 31:1272-6.
24. Kleinz MJ, Skepper JN, Davenport AP. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept 2005; 126:233-40.
25. Inoue S, Murakami Y, Sano K, Katoh H, Shimada T. Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail 2000; 6:92-96.
26. Horie H, Tsutamoto T, Minai K, Hayashi M, Kito O, Kinoshita M. Brain natriuretic peptide predicts chronic atrial fibrillation after ventricular pacing in patients with sick sinus syndrome. Jpn Circ J 2000; 64:965-70.
27. Simpkin JC, Yellon DM, Davidson SM, Lim SY, Wynne AM, Smith CC. Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemiareperfusion injury. Basic Res Cardiol 2007; 102:518-28.
28. Japp AG, Cruden NL, Amer DA, et al. Vascular effects of apelin in vivo in man. J Am Coll Cardiol 2008; 52:908-13.
29. Ehrlich J R, Hohnloser S H, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 2006 27; 512-18.